Literature DB >> 21951364

Agomelatine: protecting the CNS from the effects of stress.

Stefania Maccari, Ferdinando Nicoletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21951364      PMCID： PMC6493914          DOI： 10.1111/j.1755-5949.2010.00174.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN： 1755-5930            Impact factor:   5.243


× No keyword cloud information.
  16 in total

1.  Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus.

Authors:  O Van Reeth; L Weibel; E Olivares; S Maccari; E Mocaer; F W Turek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

2.  Effect of agomelatine in the chronic mild stress model of depression in the rat.

Authors:  Mariusz Papp; Piotr Gruca; Pierre-Alain Boyer; Elisabeth Mocaër
Journal:  Neuropsychopharmacology       Date:  2002-10-17       Impact factor: 7.853

3.  Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants.

Authors:  Laura Musazzi; Marco Milanese; Pasqualina Farisello; Simona Zappettini; Daniela Tardito; Valentina S Barbiero; Tiziana Bonifacino; Alessandra Mallei; Pietro Baldelli; Giorgio Racagni; Maurizio Raiteri; Fabio Benfenati; Giambattista Bonanno; Maurizio Popoli
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

4.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

5.  Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.

Authors:  Patrick Lemoine; Christian Guilleminault; Enric Alvarez
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

6.  Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

Authors:  Jean Pierre Olié; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2007-05-04       Impact factor: 5.176

7.  Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent.

Authors:  L Martinet; B Guardiola-Lemaitre; E Mocaer
Journal:  Pharmacol Biochem Behav       Date:  1996-08       Impact factor: 3.533

8.  Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

Authors:  H Lôo; A Hale; H D'haenen
Journal:  Int Clin Psychopharmacol       Date:  2002-09       Impact factor: 1.659

9.  Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Authors:  Mark J Millan; Mauricette Brocco; Alain Gobert; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2004-07-31       Impact factor: 4.530

Review 10.  Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Authors:  Siegfried Kasper; Michel Hamon
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.